We are live on ! Find out more
GANX icon

Gain Therapeutics
GANX

14 hedge funds and large institutions have $8.95M invested in Gain Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

17% more funds holding

Funds holding: 12 → 14 (+2)

1.35% less ownership

Funds ownership: 8.88% → 7.53% (-1.4%)

40% less capital invested

Capital invested by funds: $15M → $8.95M (-$6.08M)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$564K
2
TI
Telemetry Investments
New York
+$342K
3
BlackRock
BlackRock
New York
+$131K
4
CM
CM Management
Florida
+$113K
5
Millennium Management
Millennium Management
New York
+$107K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$982K
2
GPCM
Granite Point Capital Management
Massachusetts
-$782K
3
MS
Maven Securities
Jersey
-$340K
4
Jane Street
Jane Street
New York
-$339K
5
WVP
Worth Venture Partners
New Jersey
-$232K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$5.47M – – –
GPCM
2
Granite Point Capital Management
Massachusetts
$1.56M -$782K -69,291 -31%
PCM
3
Prelude Capital Management
New York
$581K – – –
BCM
4
Bridgeway Capital Management
Texas
$501K +$564K +50,000 New
TI
5
Telemetry Investments
New York
$303K +$342K +30,293 New
Millennium Management
6
Millennium Management
New York
$239K +$107K +9,511 +66%
BlackRock
7
BlackRock
New York
$116K +$131K +11,659 New
CM
8
CM Management
Florida
$100K +$113K +10,000 New
UBS Group
9
UBS Group
Switzerland
$41K -$22.6K -2,005 -33%
BCV
10
Banque Cantonale Vaudoise
Switzerland
$30K +$33.8K +3,000 New
Morgan Stanley
11
Morgan Stanley
New York
$8K – – –
SPIA
12
Steward Partners Investment Advisory
New York
$1K +$1.13K +100 New
ACM
13
AIGH Capital Management
Maryland
– -$982K -65,809 Closed
Jane Street
14
Jane Street
New York
– -$339K -22,754 Closed
MS
15
Maven Securities
Jersey
– -$340K -22,124 Closed
WVP
16
Worth Venture Partners
New Jersey
– -$232K -15,532 Closed
DKCM
17
Davidson Kempner Capital Management
New York
– -$222K -15,000 Closed
MA
18
MYDA Advisors
New York
– -$209K -14,000 Closed
Wells Fargo
19
Wells Fargo
California
– +$271 +24 New
TRCT
20
Tower Research Capital (TRC)
New York
– +$812 +72 New

GANX Hedge Fund Activity: Q2 2021 in Review

14 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2021, worth a combined $8.95M — down 40% from $15M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new GANX positions and 6 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $564K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $982K sold.

  • 14 institutional investors held Gain Therapeutics (GANX) as of Q2 2021, up from 12 in Q1 2021.
  • Funds reported $8.95M of Gain Therapeutics stock for Q2 2021, down 40% quarter-over-quarter.
  • 8 funds opened new Gain Therapeutics positions in Q2 2021 and 6 closed out, a net change of +2 holders.
  • The largest Gain Therapeutics buyer in Q2 2021 was Bridgeway Capital Management, an estimated $564K added.
  • The largest Gain Therapeutics seller in Q2 2021 was AIGH Capital Management, an estimated $982K sold.

Based on aggregated 13F filings for Q2 2021.